
{{Act of Congress
| congress       = 113
| session        = 1
| pl             = 1
| title          = 
| override_previous = 
| statvolume     = 
| statpage       = 
| year           = 2013
| month          = 01
| day            = 18
| bill           = 315
| billtype       = hr
| notes          = 
| resolution     = 
| purpose        = To provide for the placement of certain synthetic drugs on Schedule I under the Controlled Substances Act.
}}

{{Center|113th CONGRESS}}


{{Center|1st Session}}


{{Center|H. R. 315}}


{{Center|IN THE HOUSE OF REPRESENTATIVES}}


{{Center|January 18, 2013}}


{{Center|
[[Jo Ann Emerson|Mrs. Emerson]]
			 introduced the following bill; which was referred to the
			 [[United States House Committee on Energy and Commerce|Committee on Energy and
			 Commerce]], and in addition to the Committee on the
			 [[United States House Committee on the Judiciary|Judiciary]], for a period
			 to be subsequently determined by the Speaker, in each case for consideration of
			 such provisions as fall within the jurisdiction of the committee
			 concerned}}



{{Center|A BILL}}

To provide for the placement of certain synthetic drugs
		  on Schedule I under the Controlled Substances Act.


{{section|H48D1452207F34C93BD68692D738827CF|1. Short title}}
This Act may be cited as the
			 
          Synthetic Cathinones Control Act of
			 2013

        
.

{{section|H13644DE0FF5C4766860A6B2F57A41DAA|2. Addition of synthetic drugs to Schedule I of the Controlled Substances Act}}
(a)
In
			 general
Notwithstanding any
			 other provision of the Controlled Substances Act
 (21 U.S.C. 801 et seq.
)
, the
			 [[United States Department of Justice|Attorney General]] shall, not later than 60 days after the date of the enactment
			 of this Act, issue a final order that schedules the following substances on
			 schedule I under section 202(c) of that Act
 (21 U.S.C. 812(c)
)
:
(1)
3,4-methylenedioxymethcathinone
			 (meth­yl­one).

(2)
Naphthylpyrovalerone
			 (naphyrone).

(3)
4-fluoromethcathinone
			 (flephedrone).

(4)
4-methoxymethcathinone
			 (methedrone; Bk–PMMA).

(5)
Ethcathinone
			 (N-ethylcathinone).

(6)
3,4-methylenedioxyethcathinone
			 (ethylone).

(7)
Beta-keto-N-methyl-3,4-benzo­di­oxy­oly­bu­tan­amine
			 (butylone).

(8)
N,N-dimethylcathinone
			 (metamfepramone).

(9)
Alpha-pyrrolidinopropiophenone
			 (alpha-PPP).

(10)
4-methoxy-alphapyrrolidinopropiophenone
			 (MOPPP).

(11)
3,4-meth­yl­ene­di­oxy­alpha­pyrrol­idino­pro­pio­phe­none
			 (MDPPP).

(12)
Alpha-pyrrolidinovalerophenone
			 (alpha-PVP).

(13)
6,7-dihydro-5H-indeno[5,6-d][1,3]dioxol-6-amine
			 (MDAI).

(14)
3-fluoromethcathinone.

(15)
4′-methyl-α-pyrrolidinobutiophenone
			 (MPBP).


(b)
Conforming
			 amendment To remove deadwood

          Subsection (c) of section 202 of the
			 Controlled Substances Act
 (21 U.S.C. 802
)
 is amended to read as follows:
(c)
Cross reference
				to Schedules of Controlled Substances
Schedules I, II, III, IV, and V shall
				consist of the drugs and other substances (by whatever official name, common or
				usual name, chemical name, or brand name designated) that are set forth in the
				respective schedules in part 1308 of title 21, Code of Federal Regulations, as
				they may be amended from time to time, or in any successor
				regulation.

.




